Regev #AGBT19 Trained on 12 pts, tested on 4; shows model CD8 T-cells going with malignant cells, exclusion areas pointed out.
9:28am February 28th 2019 via Twitter Web Client
Regev #AGBT19 Looking at spatio-transcriptomics in cold vs hot malignant cells. CD8 T-cell clusters illustrated.
9:27am February 28th 2019 via Twitter Web Client
Regev #AGBT19 To learn intrinsic, extrinsic features: insi2vec method: define a cell by both features. Cell image,… https://t.co/PNXgh9hTS6
Regev #AGBT19 Toolbox - highlights alt approaches; reviews GeoMx DSP from @nanostringtech - selects ROI's of cold and hot niches.
9:23am February 28th 2019 via Twitter Web Client
Regev #AGBT19 Bulk single cell, spatial: great illustration using fruit salad vs fruit individual pieces vs fruit t… https://t.co/CUkDQnZmED
Regev #AGBT19 Multiplex in situ analysis - program char cells in cold niches. Lastly: tools to measure, track, infer and perturb.
9:22am February 28th 2019 via Twitter Web Client
Regev #AGBT19 Validation - resistance program predicts I-O outcome. Now look for drugs that affect gene exp. ID'd v… https://t.co/YcQ8R8LW3e
9:21am February 28th 2019 via Twitter Web Client
Regev #AGBT19 Used Ben Izar's method multiplexed immunoflourescence (spatial) 6 celltype markers, 7 resist program members of 19/31 pts.
9:17am February 28th 2019 via Twitter Web Client
Regev #AGBT19 Malignant cells T-cells exclusion down regulated (hot), exclusion up regulated cold. Cold: Myc, CDK4;… https://t.co/wwxOrPpKDN
9:16am February 28th 2019 via Twitter Web Client
Regev #AGBT19 Case 2: I-O response in melanoma. Durable response - about 30% for nivo + ipi. Cold vs hot tumors. 15… https://t.co/wM4VJvjkgH
9:15am February 28th 2019 via Twitter Web Client
Regev #AGBT19 Concl part 1 on UC: >50 subsets of cells; dramatic remodeling; GWAS genes are cell type-specific.
9:14am February 28th 2019 via Twitter Web Client
Regev #AGBT19 That unk gene published '18 Science https://t.co/Zi6lGCFuM7
Regev #AGBT19 Ex. C1orf106 in enterocytes: look at a gene module across all cells, then within enterocytes: co-vari… https://t.co/GOm4Mi93Ti
9:12am February 28th 2019 via Twitter Web Client
Regev #AGBT19 OSMR is a GWAS gene; mapped across 51 cell-types. Plot show cell-type-specific activity in UC. Can pr… https://t.co/GayMwZN4AE
Regev #AGBT19 Looking at a TNF bypass, when TNF is blocked, OSMR allows two cells to continue inflamm response.
9:10am February 28th 2019 via Twitter Web Client
Regev #AGBT19 One gene OSMR in Inflamm fibroblasts. Looking at anti-TNF responder vs non-responders. Chosen from '1… https://t.co/zM8BGqSCXk
9:09am February 28th 2019 via Twitter Web Client
Regev #AGBT19 Between Epithelial, Stroma, Immune cells - Healthy, Non-inflamed, Inflamed cells: bar chart shows clear differences.
9:08am February 28th 2019 via Twitter Web Client
Regev #AGBT19 GWAS highlights new causes: 94 IBD loci fine mapped from 67K individs. With a cell atlas: can see how… https://t.co/jdaBUiFEJl
9:07am February 28th 2019 via Twitter Web Client
Regev #AGBT19 Where do disease risk genes act? Which cells disrupted? Two stories: ulcerative colitis and resistance to I-O Rx in melanoma.
9:05am February 28th 2019 via Twitter Web Client
Aviv Regev (Broad Inst) #AGBT19 Cell atlases as road maps to human disease
9:04am February 28th 2019 via Twitter Web Client
Okay #AGBT19 tweeps - send Stephane some love via retweeting this handy map! https://t.co/jCEi9vZggB
2:36pm February 27th 2019 via Twitter Web Client
New post: Why is stool such a difficult non-invasive starting material for early colorectal cancer detection? An Ea… https://t.co/wrGh0wYd4u
5:18pm February 6th 2019 via Twitter Web Client
RT @ChinaBiotech: Illumina discusses the potential of NGS at #JPMHC19 #JPM19 https://t.co/1GE8Fo7hY8
8:08pm January 7th 2019 via Twitter Web Client
Current screening approaches for early cancer detection | An Early Mark blog from Singlera Genomics https://t.co/EiNIPhOuTg
8:08am November 21st 2018 via Twitter Web Client
Current early screening approaches for cancer detection | An Early Mark http:// https://t.co/ImWhzCLbpw
7:50am November 20th 2018 via Twitter Web Client
@LizWaynePhD This thread is great. Made my day, thinking about how macrophages really are the answer to life's biggest challenges.
8:44pm November 16th 2018 via Twitter Web Client in reply to LizWaynePhD
RT @Pillar_Bio: WATCH --> Helen Fernandes presented data on their work to validate #SLIMamp technology at Columbia University in a worksh
12:37pm November 16th 2018 via Twitter Web Client
RT @coregenomics: RM #AMP2018 summary slide. It’s mostly the software! https://t.co/gHcOFBfOaU
5:19pm November 2nd 2018 via Twitter Web Client
RT @coregenomics: RM #AMP2018 Lincoln et al adds significantly to our knowledge about the need for variant confirmation https://t.co/ldbTrj…
RT @coregenomics: RM published clinical studies that state confirmation not necessary #AMP2018 https://t.co/2zhOor8xUD
RT @coregenomics: RB UMIs in MSK-ACCESS #AMP2018 https://t.co/bTrThNUCrA
12:50pm November 2nd 2018 via Twitter Web Client
RT @coregenomics: RB MSK-ACCESS UMI pipeline #AMP2018 https://t.co/w0NjgVINZI
RT @coregenomics: Rose Brannon from MSKCC "Clinical Validation of MSK-ACCESS: An Ultrasensitive Next-generation Sequencing Assay for Liquid…
12:49pm November 2nd 2018 via Twitter Web Client
RT @girlscientist: Well, if there were ever a piece to get you to come to my 12pm talk on genetic literacy and the public #ASHG18, this mig…
7:41am October 18th 2018 via Twitter Web Client
If you are attending #ASHG18 at 9:45am in Room 6C Dr. Athurva Gore from @singlerainc will present "Circulating tumo… https://t.co/EkQjWjelPD
Detecting cancer four years before conventional diagnosis | LinkedIn https://t.co/siPyTzHLdC #ASHG2018 #ASHG18
8:20am October 13th 2018 via Twitter Web Client
RT @antonioregalado: THREAD: Just catching up with yesterday's Nobel in chemistry. Great picks. I'd venture the technologies honored accoun…
2:07pm October 4th 2018 via Twitter Web Client
RT @JSheltzer: The Nobel Prize in Medicine will be announced this coming Monday. You might think that the winner is a secret, but, with som…
4:02pm September 28th 2018 via Twitter Web Client
Plon #AGBTph18 As expected the majority have negative germline reports. Unexpected results include one case where g… https://t.co/hfBAvy3n4I
8:29pm September 8th 2018 via Twitter Web Client
Plon #AGBTph18 Seen a large variety of germline findings, including TP53, NF1, BRCA1/2, CHEK2, RB1, SMARCA4 in neuroblastoma.
8:25pm September 8th 2018 via Twitter Web Client
Plon #AGBTph18 Blood samples, 2w TAT, shows MATCHBOX plus germline modification. Goal 1500; study started Aug '17; n=296 as of today.
8:24pm September 8th 2018 via Twitter Web Client
Plon #AGBTph18 Not all cancer suscept genes are included (e.g. DICER1). Genetic counselling available, educational resources.
8:22pm September 8th 2018 via Twitter Web Client
Plon #AGBTph18 What is missing: not systematic sequencing of genes (as if for germline). Adult MATCH: did not inter… https://t.co/IXvSzppByP
8:21pm September 8th 2018 via Twitter Web Client
Plon #AGBTph18 Two dedicated labs (CHLA, Baylor) reoutinely report herid cancer results; pathogenic, likely path, VUS if included on report.
8:20pm September 8th 2018 via Twitter Web Client
Plon #AGBTph18 Two-hit hypothesis: RB1, WT1, TP53, NF1: same gene may undergo somatic or germline mutations.
8:17pm September 8th 2018 via Twitter Web Client
Plon #AGBTph18 Combined RNA and DNA, 140 genes. About 10% of unselected ped cancer pts have underlying germline mutations
8:16pm September 8th 2018 via Twitter Web Client
Plon #AGBTph18 COG - Children's Oncology Group. Nothing about germline analysis is a primary obj. Relapse, and refr… https://t.co/UIIp72Mzy3
8:13pm September 8th 2018 via Twitter Web Client
Plon #AGBTph18 PEC-MATCH: Project Every Child; a COG-wide single-stage PhII trial of genomically-directed Rx for ch… https://t.co/nKBxPY7oNe
8:11pm September 8th 2018 via Twitter Web Client
Sharon Plon (Baylor) #AGBTph18 Germline reporting in the National Cancer Institute – Children’s Oncology Group (NCI… https://t.co/vvUc33g0Ta
8:10pm September 8th 2018 via Twitter Web Client
Berger #AGBTph18 '17 ref https://t.co/zfjJcYEjFT Treating pts based on novel hotspot muts, basket trial efficacy.
7:44pm September 8th 2018 via Twitter Web Client
